ABSTRACT
OBJECTIVES: To quantify the potential harm of beta blockers in patients with peripheral arterial disease. MATERIALS AND METHODS: All randomised controlled trials (RCTs) comparing beta blockers with placebo for the outcomes of claudication and maximal walking distance and time, calf blood flow, vascular resistance and skin temperature were searched using the Cochrane Controlled Trials Register, PubMed and CINAHL. Trials comparing different types of beta blockers were excluded. RESULTS: Six RCTs fulfilling the above criteria, with a total of 119 patients, were included. The beta blockers studied were atenolol, propranolol, pindolol and metoprolol. None of the trials showed a statistically significant worsening effect of beta blockers on the outcomes measured. There were no reports of any adverse events with the beta blockers studied. CONCLUSIONS: Currently, there is no evidence to suggest that beta blockers adversely affect walking distance in people with intermittent claudication. Beta blockers should be used with caution if clinically indicated, especially in patients with critical ischaemia where acute lowering of blood pressure is contraindicated.
Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Peripheral Vascular Diseases/drug therapy , Humans , Intermittent Claudication/drug therapy , Intermittent Claudication/physiopathology , Peripheral Vascular Diseases/physiopathology , Randomized Controlled Trials as Topic , Treatment Outcome , Vascular Resistance/drug effectsSubject(s)
Analgesics/administration & dosage , Dermatologic Surgical Procedures , Face/surgery , Pain, Postoperative/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Ambulatory Surgical Procedures , England , Female , Humans , Male , Middle Aged , Pain Measurement/methods , Prospective StudiesABSTRACT
OBJECTIVE: To discover the impact of topical negative pressure (TNP) on quality of life. METHOD: An exploratory prospective cohort study was conducted on 26 patients undergoing TNP. The Cardiff Wound Impact Schedule (CWIS), a wound-specific tool, was used to investigate quality-of-life scores before therapy and four weeks after therapy or at wound closure. Wound dimensions were measured at both assessments, and the values for the CWIS domains (physical symptoms, social functioning, well-being and overall quality of life) were investigated using parametric and non-parametric tests. RESULTS: The mean duration of TNP therapy was 3.3 +/- 1.7 weeks. Topical negative pressure therapy helped to achieve complete wound closure in 14 patients (54%), and there was a mean reduction in wound surface area from 52.2 cm2 (range 4-150) to 26.8 cm2 (0-120). While there was no significant change in quality of life in patients whose wounds healed (1 +/- 11.9), the physical-functioning domain improved in obese patients (20 +/- 21, p < 0.05) and worsened in ambulatory patients (-3 +/- 13, p < 0.05). The portableTNP system had no significant impact on quality of life (-3 +/- 16), while the global quality-of-life score worsened with surgical intervention (-0.5 +/- 2, p < 0.05). CONCLUSION: Although TNP aids wound closure in patients with complex wounds, in selected cases their quality of life can worsen. This is the first exploratory cohort study of its kind, and has identified an urgent need to validate the use of patient-based outcome measures in TNP therapy. Such data can be useful in allocating resources and justifying funding in wound care.
